Abivax (AAVXF) Tax Provisions (2025 - 2026)
Abivax (AAVXF) posted Tax Provisions of -$266930.0 for Q1 2026, up 96.08% on a QoQ basis from -$6.8 million in Q4 2025.
Powered by 
Analysis
Abivax (AAVXF) Tax Provisions (2025 - 2026) Analysis & Trends
Abivax has reported Tax Provisions for 2 years, with the latest figure at -$266930.0 in Q1 2026.
- On a quarterly basis, Tax Provisions changed N/A year-over-year to -$266930.0 in Q1 2026; TTM through Mar 2026 was -$7.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$6.8 million, changed N/A from the prior year.
- Tax Provisions was -$266930.0 for Q1 2026 at Abivax, up from -$6.8 million in the prior quarter.
- The five-year high for Tax Provisions was -$266930.0 in Q1 2026, with the low at -$6.8 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | 393.00 Mn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | 242.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | 292.00 Mn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | 230.90 Mn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | -59.00 Mn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | 15.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | 13.31 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | 34.90 Mn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | -3.96 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - | -266,930.01 |